Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Pain (mean score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Clinical resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Clinical resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Xerostomia (dry mouth relief) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Johnson 1993: positive response (>25 mm change in VAS score) in 25% of participants on placebo, 51% on pilocarpine 5 mg tds, 47% on pilocarpine 10 mg tds. LeVeque 1993: positive response in 7% on placebo vs 42% on…
2 studies · 278 participants
GRADE not reported
Other oral symptoms (oral discomfort, dysphonia) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Both studies assessed oral discomfort and dysphonia (Johnson 1993; LeVeque 1993); pilocarpine reported to improve associated symptoms of salivary gland dysfunction (oral discomfort, dysphonia). No pooled data.
2 studies · 278 participants
GRADE not reported
Salivary flow rate · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Adverse effects (side effects; treatment withdrawals) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Johnson 1993 (5 mg tds): sweating 37%, headache 15%, urinary frequency 14%, vasodilatation 12%, dizziness 10%, dyspepsia 10%, nausea 8%, asthenia 8%, diarrhoea 5%; 6% withdrew at 5 mg tds and 29% at 10 mg tds. LeVeque…
2 studies · 278 participants
GRADE not reported
Other oral symptoms (dysgeusia, dysphagia) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Dry mouth (xerostomia) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Davies 1994 (cross-over, 20 participants): mean improvement in VAS score 22.5 mm with pilocarpine vs 15.2 mm with artificial saliva (100 mm scale). The improvement was greater with pilocarpine but was not statistically…
1 study · 20 participants
GRADE not reported
Adverse effects (side effects; treatment withdrawals) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Davies 1994: main side effects with pilocarpine were nausea 20%, sweating 15%, lacrimation 10%. One participant definitely withdrew because of side effects; another may have.
1 study · 20 participants
GRADE not reported
Parasympathomimetic drugs (choline esters, cholinesterase inhibitors) vs No treatment
Outcome not reported · Patients with radiation-induced salivary gland dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Indomethacin showed no clear difference in oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Pain resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether dexamethasone ointment changes pain resolution compared with amlexanox paste (very low certainty).
1 finding from 1 review
Pain (mean score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Dexamethasone ointment showed no clear difference in pain (mean score) compared with amlexanox paste; GRADE not reported.
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Goel 2015 (3-arm: intralesional betamethasone vs lycopene vs placebo, 90 per arm): appeared to show increased interincisal distance in both intervention groups vs placebo, but only between-group differences with no…
1 study · 180 participants
GRADE not reported
Clinical resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Intralesional betamethasone may leads to higher clinical resolution compared with intralesional triamcinolone acetonide (low certainty).
1 finding from 1 review
Clinical score (14 days) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether intralesional betamethasone changes clinical score (14 days) compared with intralesional triamcinolone acetonide (very low certainty).
1 finding from 1 review
Pain (mean score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Intralesional betamethasone showed no clear difference in pain (mean score) compared with intralesional triamcinolone acetonide (low certainty).
1 finding from 1 review
Clinical score · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether systemic (oral) betamethasone changes clinical score compared with topical triamcinolone acetonide paste (very low certainty).
1 finding from 1 review